BIOCRYST PHARMACEUTICALS INC (BCRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 163,353 | 145,534 | 117,085 | 109,332 |
| Royalty | - | - | 17 | 35 |
| Selling, general and administrative | 87,383 | 82,469 | 65,084 | 61,214 |
| Research and development | 43,386 | 37,270 | 41,081 | 37,623 |
| Cost of product sales | 2,798 | 4,568 | 3,211 | 1,699 |
| Total operating expenses | 133,567 | 124,307 | 109,393 | 100,571 |
| Income (loss) from operations | 29,786 | 21,227 | 7,692 | 8,761 |
| Interest expense | 21,582 | 23,494 | 24,828 | - |
| Interest income | 2,516 | 3,024 | 3,591 | 3,554 |
| Loss on extinguishment of debt | -4,171 | - | - | - |
| Foreign currency losses, net | -63 | 1 | 98 | -84 |
| Total other expense | -23,300 | -20,469 | - | - |
| Interest expense | - | - | - | 24,733 |
| Income (loss) before income taxes | 6,486 | 758 | -13,447 | -12,502 |
| Income tax expense | 1,401 | 726 | 586 | 172 |
| Net income (loss) | 5,085 | 32 | -14,033 | -12,674 |
| Unrealized loss on available for sale investments | -188 | -155 | - | - |
| Foreign currency translation adjustment | 702 | 366 | 563 | -140 |
| Total other comprehensive income (loss) | 514 | - | - | - |
| Total other comprehensive income (loss) | - | 211 | - | - |
| Unrealized gain on available for sale investments | - | - | 1,173 | -74 |
| Net comprehensive income (loss) | 5,599 | 243 | -12,297 | -12,888 |
| Basic net loss per common share (in usd per share) | 0.02 | - | -0.07 | -0.06 |
| Diluted net loss per common share (in usd per share) | 0.02 | - | -0.07 | -0.06 |
| Weighted average shares outstanding, basic (in shares) | 209,519,000 | 208,882,000 | 206,905,000 | 206,425,000 |
| Weighted average shares outstanding, diluted (in shares) | 219,886,000 | 215,261,000 | 206,905,000 | 206,425,000 |